Printer Friendly

BIOCIUS Life Sciences and BlueSky Biotech Extend Partnership, Provide Validated Enzymes.

Fully-validated SIRT1 Enhances Drug Discovery Investigation

WAKEFIELD, Mass. & WORCESTER, Mass. -- BIOCIUS Life Sciences Inc., developers of the RapidFire[R] high-throughput mass spectrometry system, and BlueSky Biotech, service provider of discovery biologicals, today announced their collaboration to offer the industry's only Sirtuin (SIRT, silent mating type information regulation homolog) enzyme preparations fully-validated in a label-free functional assay. This collaboration builds on an existing partnership and will significantly improve drug discovery efficiency of the SIRT class of epigenetic modulating enzymes, which are being heavily investigated as promising therapeutics for several indications.

"Our latest endeavor with BIOCIUS provides researchers with a pre-validated assay solution that saves time and money, and further demonstrates the synergy of our high quality proteins combined with BIOCIUS's value-added screening solutions " said Paul Wengender, CEO, Blue Sky Biotech, Inc. According to William LaMarr, Vice President of Research and Contract Services at BIOCIUS, "validation using a label-free, functional assay is especially important for sirtuins given the controversy surrounding fluorescent based assays recently seen in the scientific literature."

The collaboration intends to launch a selectivity panel of sirtuins and histone deacetylases (HDACs). The activity of the first release, SIRT1, has been linked to the regulation of multiple cellular processes including insulin signaling, apoptosis, and cancer, making SIRT1 an important therapeutic target for a variety of conditions. The two companies plan to release additional validated enzymes over the course of the coming months.

About BIOCIUS Life Sciences, Inc.

Named from the Greek word "BIO" (life) and the Latin word "OCIUS" (faster), BIOCIUS Life Sciences, provides the biopharmaceutical industry with faster answers: Products and services committed to speed and accuracy in drug discovery. Used by 13 of the top 15 pharmaceutical companies, BIOCIUS's products and contract research services enable our partners to exceed their business goals.

About BlueSky Biotech

Blue Sky Biotech, Inc. is an integrated provider of custom biologicals for biomedical research and drug discovery and is organized into two divisions: BioServices and BioProducts. The BioServices division offers a wide range of custom services spanning Molecular Biology, Eukaryotic and Prokaryotic Protein Expression, Protein Purification, and Assay Development. This suite of pre-clinical services provides our clients with a convenient source of high quality custom research tools. Blue Sky also invests heavily in technology development to improve or enhance its production capabilities, including a proprietary process technology (IKM[R]) that significantly reduces cycle times and enhances reproducibility of protein production using baculovirus-mediated insect cell expression. The BioProducts division offers high quality biologicals and membrane protein solutions (TDA[TM] and Smartscreen(TM)Kits) designed to facilitate drug discovery. The company is a privately held corporation with over 40 staff members. It is located in Worcester, MA. For more information, please visit www.blueskybiotech.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6327292&lang=en
COPYRIGHT 2010 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 15, 2010
Words:464
Previous Article:Emeritus Senior Living Partners with Fit Brains to Further Develop Brain Health Lifestyle.
Next Article:Blackbaud Index of Charitable Giving Reports 12.1 Percent Increase in Overall Giving.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters